NOVO-NORDISK A/S-SPONS ADR (NVO)

US6701002056 - ADR

128.05  -1.36 (-1.05%)

After market: 127.5 -0.55 (-0.43%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

NOVO-NORDISK A/S-SPONS ADR

NYSE:NVO (3/27/2024, 8:04:00 PM)

After market: 127.5 -0.55 (-0.43%)

128.05

-1.36 (-1.05%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap571.41B
Shares
PE47.25
Fwd PE37.97
Dividend Yield1.05%
Analysts
IPO
Stock Screener Links
Screen Image

New York Stock Exchange, Inc. Stock Screener

Find more stocks on New York Stock Exchange, Inc.

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Growth Stock Screener

Find more growth stocks the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

NVO Daily chart

Company Profile

Novo Nordisk A/S is a DK-based company operating in Pharmaceuticals industry. Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The firm is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The firm operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The firm's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The firm's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The firm also offers Saxenda product to treat obesity. The company offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.

Company Info

NOVO-NORDISK A/S-SPONS ADR

Novo Alle 1

Bagsvaerd 2880

P: 4544448888

CEO: Lars Fruergaard Jorgensen

Employees: 61412

Website: https://www.novonordisk.com/

NVO News

News Imagea day ago - InvestorPlaceThe 2025 Double: 3 Stocks Poised to Deliver 100% Gains in Just 12 Months

Let's review what Wall Street analysts believe are potentially the stocks to double over the next 12 months.

News Image2 days ago - InvestorPlace3 Stocks to Buy for the Next Bull Run: March 2024

Look for these stocks to buy to continue moving higher in coming quarters propelled by multiple catalysts and strong earnings.

News Image2 days ago - The Motley FoolNovo Nordisk and Nvidia Just Partnered on AI. Is the Stock a Buy?

Their joint project is cutting-edge, but it won't pay off immediately.

News Image2 days ago - Investor's Business DailyViking Surges After Weight-Loss Pill Tops Expectations In Just 28 Days

People lost more weight than the company expected over a 28-day study.

News Image2 days ago - The Motley FoolBest Obesity Drug Stock: Eli Lilly, Novo Nordisk, or Viking Therapeutics?

All three of these high-flying stocks could have more room to run.

News Image2 days ago - Investor's Business DailyDexcom Stock Shows Market Leadership, Gets Rating Upgrade. Prognosis Good.

Among its other key ratings Dexcom has a near-best 98 Earnings Per Share Rating out of 99, reflecting strong profit growth this past year.

NVO Twits

Here you can normally see the latest stock twits on NVO, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example